Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Atrys Health, S.A.
  6. Summary
    ATRY   ES0105148003

ATRYS HEALTH, S.A.

(ATRY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
10.95(c) 11.05(c) 10.8(c) 10.6(c) 10.8(c) Last
2 372 15 063 3 692 5 217 17 393 Volume
+0.46% +0.91% -2.26% -1.85% +1.89% Change
More quotes
Estimated financial data (e)
Sales 2021 126 M 147 M 147 M
Net income 2021 6,00 M 7,04 M 7,04 M
Net Debt 2021 90,0 M 106 M 106 M
P/E ratio 2021 71,9x
Yield 2021 -
Sales 2022 202 M 237 M 237 M
Net income 2022 23,0 M 27,0 M 27,0 M
Net Debt 2022 60,0 M 70,4 M 70,4 M
P/E ratio 2022 31,2x
Yield 2022 -
Capitalization 661 M 776 M 775 M
EV / Sales 2021 5,97x
EV / Sales 2022 3,56x
Nbr of Employees 525
Free-Float 57,9%
More Financials
Company
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine,... 
More about the company
Ratings of Atrys Health, S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ATRYS HEALTH, S.A.
09/01Atrys Health, S.A. completed the acquisition of GENETYCA – ICM, S.A.
CI
06/07Atrys Health, S.A. signed an agreement to acquire Genetyca.
CI
05/11An unknown buyer acquired 5% stake in Atrys Health, S.A. from Inversiones Ind..
CI
05/06ATRYS HEALTH S A : 2020 Consolidated financial statements (EN).
PU
04/27ATRYS HEALTH S A : Presentación avance de resultados ejercicio 2020.
PU
04/27ATRYS HEALTH S A : increased its turnover by 112% in 2020, to 31.4 million
PU
04/21ATRYS HEALTH S A : achieves the acceptance of its acquisition offer for Aspy
PU
04/21Atrys Health, S.A. completed the acquisition of Aspy Global Services S.L. (So..
CI
02/25ATRYS HEALTH S A : The study led by Atrys and Vithas on the impact of Covid-19 i..
PU
02/25ATRYS HEALTH S A : The study led by Atrys and Vithas on the impact of Covid-19 w..
PU
02/25ATRYS HEALTH S A : The study led by Atrys and Vithas on the impact of Covid-19 w..
PU
02/25ATRYS HEALTH S A : The study led by Atrys and Vithas on the impact of Covid-19 i..
PU
02/25ATRYS HEALTH S A : The scientific study led by Atrys and Vithas on the impact of..
PU
02/25ATRYS HEALTH S A : acquires the Swiss Radio-onkologie Amsler AG
PU
02/08Kantaro and Atrys Health Partnership Expand Global Footprint of Quantitative ..
CI
More news
News in other languages on ATRYS HEALTH, S.A.
09/16ATRYS HEALTH S A : y Sanitas abrirán en Madrid la segunda sede del Instituto de ..
09/16ATRYS HEALTH S A : Sanitas y Atrys abrirán en Madrid la segunda sede del Institu..
09/16ATRYS HEALTH S A : Sanitas y Atrys abrirán en Madrid la segunda sede del Institu..
07/27ATRYS HEALTH S A : aterriza en Portugal
06/08ATRYS HEALTH S A : refuerza su presencia en Portugal con la compra de Genetyca I..
More news
Chart ATRYS HEALTH, S.A.
Duration : Period :
Atrys Health, S.A. Technical Analysis Chart | ATRY | ES0105148003 | MarketScreener
Technical analysis trends ATRYS HEALTH, S.A.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 10,80 €
Average target price 11,39 €
Spread / Average Target 5,42%
EPS Revisions
Managers and Directors
Isabel Lozano Fernandez Chief Executive Officer & Executive Director
Jose María Huch Ginesta Chief Financial Officer
D. Santiago de Torres Sanahuja Chairman
Jaime Cano Fernández Independent Director
Jaime del Barrio Seoane Independent Director
Sector and Competitors